PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

Inclusion Criteria: Patients treated at DUMC, DFCI, MDACC, MGH, NWH, or DFCI @ SSH with a diagnosis of DCIS, LCIS, ADH, or ALH who are also: * Age 18 or more at index diagnosis * Diagnosed with DCIS, LCIS, ADH, or ALH between January 1, 2012 and June 30, 2017 * Able to read either English or Spanish and able to provide written (via paper), or on-line informed consent * Treated and followed at one of the study sites (including affiliated network sites) and for whom treatment and surveillance data are available, for at least 1 year of follow up after date of diagnosis * Participants with bilateral synchronous or metachronous disease (DCIS, LCIS, ADH, ALH) are eligible Exclusion Criteria: * Ever had a diagnosis of invasive or microinvasive breast cancer * DCIS prior to index lesion or history of progressive/recurrent DCIS after treatment * Other cancers (excluding non-melanoma skin cancer) diagnosed within 5 years prior to index lesion, including concurrent invasive cancer diagnosis and up to the present time of participant's approach to invitation into the study * Patients identified by treating physician as being unsuitable for contact